Member Info for Timster

Nice post PL75, those figures are fantastic, and not at all concerning.

From the initial clinical validation RNS:
These data from the first clinical studies will allow us to quickly progress with confidence into the full clinical validation of the test, manufactured at scale, at our clinical trial sites in the UK and the EU. I am confident that these data will accelerate our commercial discussions regarding the roll-out of the test when it is approved for professional use.

"clinical trial sites in the UK and EU"

So today's result is from the EU site, wonder if we will get a UK update soon....

Interesting that only GAD are mentioned today, are they handling all of our overseas production?

Is there and BBI and Abingdon announcement due for UK capacity?

As part of the study the same clinical samples were tested with two leading, commercially available lateral flow antigen tests, and the data show that the AffiDx® test had better clinical sensitivity across the range of Ct value and in particular at lower viral loads.

https://www.google.com/amp/s/www.mirror.co.uk/news/politics/boris-johnson-hold-downing-street-23944861.amp

Is it us?

the reverse psychology worked :)

Special mention to tsales, mumbo jumbo gkb et al no test lol, here's your ****ing test.....and it's best in class...

Great result obvioisly as expected.

We were all expecting a validation on thousands of samples. Why only 98?

This isn't a phase 3 validation for porton down perhaps that is still to come.

Does seem this is the first RNS which is specifically talking about sales in Europe, is it an "up yours" to UK gov or is that RNS still to come

Poor old visainn...

Number 43 fits BAMS

Not even odx's RNS moved us today, shocker!

Still would appear number 45 fits Avacta and it's the only lateral flow test in the running
https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/products-in-the-pipeline-tvg-validation-concluded-or-paused

45 Point of care test Lateral flow Processing through alternative routes

Don't know about Avacta's AffiDX® SARS-CoV-2 Lateral Flow Rapid Antigen Test being garbage, the quality of posts certainly is though.
Not much can be said now though I guess. We just wait to see if large scale validation confirms the 56 CV statement:

In summary, the AffiDX® SARS-CoV-2 Lateral Flow Rapid Antigen Test has excellent analytical sensitivity (LOD) of 50 pg/ml S1 spike protein, which appears sensitive enough to detect the lowest viral loads of relevance to the Intended Use Case, with a read time of 20 minutes. As far the Group is aware, this is the most sensitive S1 spike lateral flow test available.
The analytical specificity of the Affimer reagents has been reported previously with no cross-reactivity with the S1 spike proteins from closely related coronaviruses: MERS-CoV S1, SARS-CoV-1 S1, HC0V-229E S1, HCoV-HKU1 S1, HCoV-NL63 S1 or HCoV-OC43 S1.
The test detects the D641G mutant of the original coronavirus and the Group expects that the test will also detect the newer coronavirus variants. Work is ongoing with Public Health England to confirm this.

The mainstream poo pooong of the Chinese test begins.

Make way for avacta

Only just noticed as well that Chris Miller and Fran Mullen are Business Development for North America, what would Avacta need with them?

And look where Fran came from:
Prior to joining Avacta, she was a key account manager for Abcam, supporting pharmaceutical and biotech companies with a portfolio of antibodies, assays and proteins. Before this, she sold custom peptide synthesis services in the Mid-Atlantic and Southeast regions of the US for CPC Scientific and AnaSpec, Eurogentec Group.

Remember this from last year?
https://www.medusa19.com/en/news/medusa-19-launches-landmark-madrid-covid-trials-to-reopen-universities-263691/

Seems hard to believe they will need 50 million of thier test ...

Xray I expect mortgage has already emailed Al to suggest that. What a great idea...

https://twitter.com/BQuilty/status/1383437545296470026?s=19

Findings Most of the rapid antigen LFDs showed a high specificity (>98%), and accurately detected 50 PFU/test (equivalent N1 Ct of 23.7 or RNA copy number of 3×106/ml). Sensitivities of the LFDs performed on clinical samples ranged from 65 to 89%. These sensitivities increased in most tests to over 90% for samples with Cts lower than 25. Positive virus culture was achieved for 57 out of 141 samples, with 80% of the positive cultures from swabs with Cts lower than 23. Importantly, sensitivity of the LFDs increased to over 95% when compared with the detection of infectious virus alone, irrespective of Ct. Longitudinal studies of PCR-positive samples showed that most of the tests identified all infectious samples as positive, but differences in test sensitivities can lead to missed cases in the absence of repeated testing. Finally, test performance was not impacted when re-assessed against swabs positive for the dominant UK variant B.1.1.7.

And from our initial CV
30 positive samples were tested with Ct values of 26 and below, with half of those in the range 22-26, and the lateral flow test identified 29/30 of these correctly as positive. This indicates a clinical sensitivity of 96.7% for samples with a Ct value below 26. Importantly, out of a total of 26 negative samples tested with the lateral flow device, the test correctly identified all 26 as negative, giving a clinical specificity of 100%.

BBC News - Covid: Gig with no social distancing to be part of government pilot
https://www.bbc.co.uk/news/uk-56789454

Good point radia the "cardboard box" company as one twat called them seem to be doing alright